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Background:The purpose of this study was to compare posttransplantation morbidity and mortality in orthotopic
heart transplant recipients bridged to transplant with a left ventricular assist device with nonbridged recipients. To
account for potential differences across device types, we stratified bridge-to-transplant recipients by type of
ventricular assist device: extracorporeal (EXTRA), paracorporeal (PARA), and intracorporeal (INTRA).
Methods: The United Network for Organ Sharing provided de-identified patient-level data. The study population
included 10,668 orthotopic heart transplant recipients aged 18 years old or older and undergoing transplantation
between January 1, 2001, and December 31, 2006. Follow-up data were provided through August 3, 2008, with
a mean follow-up time of 3.17  2.15 years (range, 0–8.11 years). The primary outcome was actuarial post-
transplant graft survival. Other outcomes of interest included infection, stroke, and dialysis during the transplant
hospitalization; primary graft failure at 30 days; transplant hospitalization length of stay; and long-term compli-
cations including diabetes mellitus, transplant coronary artery disease, and chronic dialysis. Multivariable Cox
proportional hazards regression (backward, P< .15) was used to determine the relationship between groups
and overall graft survival, and multivariable logistic regression analysis (backward, P< .15) was used to
determine the relationship between groups and secondary outcome measures.
Results: In multivariable Cox regression analysis, when compared with the nonbridged group, risk-adjusted greater
than 90-day graft survival was diminished among the EXTRA group (hazard ratio¼ 3.54, 2.28–5.51, P<.001), but
not the INTRA group (1.04, 0.719–1.51, P¼ .834) or the PARA group (1.06, 0.642–1.76, P¼ .809). There were no
significant differences in risk-adjusted graft survival across the 4 groups during the 90-days to 1-year or 1- to 5-year
intervals. However, at more than 5 years, risk-adjusted graft survival in the INTRA group (0.389, 0.205–0.738, P¼
.004)was better than in the nonbridgedgroup.TheEXTRA,PARA, and INTRAgroups all experienced increased risks
of infection. The EXTRA group had increased risks of dialysis, stroke, and primary graft failure at 30 days, whereas
neither the PARA nor the INTRA group differed from the nonbridged group. Long-term complications did not differ
by group.
Conclusion: The use of implantable left ventricular assist devices as bridges to transplantation, including both
intracorporeal and paracorporeal devices, is not associated with diminished posttransplant survival. However,
90-day survival was diminished in recipients bridged with extracorporeal devices. (J Thorac Cardiovasc Surg
2009;138:1425-32)
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doi:10.1016/j.jtcvs.2009.07.034The Journal of Thoracic and CaVentricular assist devices (VADs) are crucial in the manage-
ment of heart transplant candidateswhose condition becomes
refractory to medical therapy while they are awaiting trans-
plantation.1,2 Over the past decade, the number of heart
transplant recipients supported by VADs at the time of trans-
plantation has more than doubled to over 400 per year.3
Although numerous studies have demonstrated the benefits
of VADs in the pretransplant period,1,2 findings from studies
examining the impact of VADs on posttransplant outcomes
have conflicted. The majority of studies have concluded that
short-term, but not long-term, survival is diminished in recip-
ients bridged with VADs.4.5 More recently, an analysis of the
United Network for Organ Sharing (UNOS) registry6 con-
cluded that during the study period (1995–2004), there was
a significant increase in late, but not early, mortality among
those implanted with intracorporeal devices.rdiovascular Surgery c Volume 138, Number 6 1425
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XAbbreviations and Acronyms
BTT ¼ bridge to transplantation
EXTRA ¼ extracorporeal ventricular assist device
INTRA ¼ intracorporeal ventricular assist device
LVAD ¼ left ventricular assist device
PARA ¼ paracorporeal ventricular assist device
UNOS ¼ United Network for Organ Sharing
VAD ¼ ventricular assist device
The purpose of this study was to compare posttransplanta-
tion survival in nonbridged orthotopic heart transplant recip-
ients with survival of recipients bridged to transplant (BTT)
with extracorporeal (EXTRA), paracorporeal (PARA), and
intracorporeal (INTRA) left ventricular assist devices
(LVADs) during the period 2001 through 2006. Further-
more, this study examined the relationship between VAD-
type and in-hospital morbidity, including stroke, infection,
and need for dialysis; primary graft failure at 30 days; trans-
plant hospitalization length of stay; and the long-term com-
plications including diabetes mellitus, transplant coronary
artery disease, chronic dialysis, and rejection.
For this analysis, we chose to focus on the more recent pe-
riod, becauseVAD technology and its application have under-
gone important changes since the completion of REMATCH
(Randomized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure) in 2001.7 First, there
have been incremental improvements in the device by manu-
facturers.8 Concurrently, with growing experience, clinicians
have improved their management of LVADpatients including
modifications in the operative procedure, adoption of practices
that decrease driveline infections, and changes in anticoagula-
tion regimens, which reduced the adverse event profile associ-
ated with devices. With these advances, a number of
investigators have reported improved clinical as well as eco-
nomic outcomes9,10 with device therapy. In addition, this pe-
riod includes early experience with newer generation
pulsatile devices. Therefore, this more recent period may be
more generalizable to the current era.
METHODS
Data Collection
Use of these data is consistent with the regulations of Columbia Univer-
sity’s Institutional Review Board. UNOS provided de-identified event-level
data from the Thoracic Registry (data source #030309-3), where each obser-
vation represents a heart transplant. These data include all heart transplants
and associated donors in the United States and reported to the Organ Pro-
curement and Transplantation Network since October 1987. Data entry by
all US transplant centers is mandated by the 1984 National Transplantation
Act.
Study Population
The study population included 10,989 orthotopic heart transplants
among recipients aged 18 years old or more and undergoing transplanta-1426 The Journal of Thoracic and Cardiovascular Stion between January 1, 2001, and December 31, 2006. Follow-up data
were provided through February 20, 2009. Recipients were stratified
into 4 groups: standard/nonbridged (non-BTT), extracorporeal (EXTRA),
intracorporeal (INTRA), and paracorporeal (PARA). EXTRA devices in-
cluded Abiomed BVS5000 (Abiomed Inc, Danvers, Mass), TandemHeart
(Cardiac Assist, Inc, Pittsburgh, Pa), Bio-Medicus (Medtronic Bio-Medi-
cus, Eden Prairie, Minn), and Levitronix/Centrimag (Levitronix LLC,
Waltham, Mass). PARA devices included Abiomed AB5000, Thoratec
PVAD (Thoratec Corporation, Pleasanton, Calif), and Toyobo (Toyobo,
Osaka, Japan). INTRA devices included pulsatile devices (Novacor
[Novacor; World Heart Inc, Oakland, Calif], HeartMate I [Thermo Cardi-
osystems, Inc, Woburn, Mass], Thoratec IVAD, and LionHeart [Arrow In-
ternational, Inc, Reading, Pa]) and continuous-flow devices (HeartMate II,
MicroMed/Debakey [MicroMed Technology Inc., Houston, Tex], Jarvik
[Jarvik Heart, Inc, New York, NY], and Ventracor/VentrAssist [Ventra-
cor, Sydney, Australia). Devices designated as ‘‘Abiomed’’ only were
classified as ‘‘Abiomed BVS5000,’’ and devices designated as ‘‘Thora-
tec’’ only were classified as ‘‘Thoratec PVAD.’’ In secondary analysis,
the INTRA group was substratified into pulsatile and continuous-flow
groups. Because the purpose of the study was to better understand survival
in BTT with LVADs, recipients were excluded if they were supported
with a total artificial heart (n ¼ 49, 0.45%), extracorporeal membrane
oxygenation (n ¼ 40, 0.36%), a right VAD (n ¼ 22, 0.20%), or if the
VAD type was unknown (n ¼ 14, 0.13%). In addition, patients who un-
derwent a simultaneous transplant of another organ (n ¼ 255, 2.32%)
were excluded.
Outcome Measures
The primary outcome measure was actuarial posttransplant graft sur-
vival. Risk-adjusted survival, derived from multivariate Cox regression
analysis, was expressed as hazard ratios with 95% confidence intervals.
Secondary outcome measures included transplant hospitalization morbid-
ity measured by incidence of stroke, infection, and need for dialysis during
the transplant hospitalization, as well as primary graft failure at 30 days.
Long-term complications, which were reported as incidence rates, in-
cluded diabetes, transplant coronary artery disease, chronic dialysis, and
severe rejection.
Data Analysis
Continuous variables were reported as means standard deviations and
compared by the Student t test. The c2 test was used to compare categorical
variables. All reported P values are 2 sided.
Survival and Other Time-to-Event Analyses
Kaplan–Meier analysis was used to calculate actuarial survival. For sur-
vival analysis, the outcome of interest was death (n ¼ 2585, 24.3%) or
retransplantation (n ¼ 119, 1.11%). Other patients, including those lost
to follow-up (n ¼ 363, 3.40%) or alive at last follow-up (n ¼ 7601,
71.3%), were censored on the day of last known follow-up. To assess
the simultaneous effect of multiple variables on graft survival after heart
transplant, we used multivariable Cox proportional hazards regression
(backward, P< .15) to determine the relationship between groups and
overall graft survival. Proportional hazards assumption was examined for
each of the variables using the Schoenfeld residuals test to assess propor-
tionality. For variables demonstrating a significant interaction with time,
the interaction term with time was included in the final regression model.
Because the relationship between survival and VAD type was found to be
time dependent, the hazard ratios for VAD types during various time inter-
vals (<90 days, 90 days–1 year, 1–5 years, and>5 years) were reported.
Multivariable logistic regression analysis (backward, P< .15) was used
to determine the relationship between groups and secondary outcome mea-
sures. Long-term complications were reported as incidence rates per 100
patient-years.urgery c December 2009
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Study Population (Table 1)
Analysis included 10,668 orthotopic heart transplantswith
a mean follow-up time of 3.54  2.10 years (range, 0–8.11
years). Recipients were stratified into 4 groups: INTRA
(n ¼ 1680, 15.7%), PARA (n ¼ 514, 4.8%), EXTRA
(n ¼ 128, 1.2%), and non-BTT (n ¼ 8346, 78.2%).
Posttransplant survival. Unadjusted graft survival
(Figure 1) was not different in the INTRA (P ¼ .737)
group when compared with the non-BTT group; however,
when compared with the non-BTT group, survival was
significantly worse in the EXTRA group (P< .001) and
the PARA group (P< .001). In multivariate Cox regres-
sion analysis (Appendix E1), when compared with the
non-BTT group, risk-adjusted less than 90-day graft sur-
vival was diminished among the EXTRA group (hazard
ratio ¼ 3.54, 2.28–5.51, P< .001), but not the INTRA
group (1.04, 0.719–1.51, P ¼ .834) or PARA group
(1.06, 0.642–1.76, P ¼ .809). There were no significant
differences in risk-adjusted graft survival across the 4
groups during the 90-days to 1-year interval or 1- to 5-
year interval. However, at more than 5 years, risk-adjusted
graft survival in the INTRA group (0.389, 0.205–0.738, P
¼ .004) was better than in the non-BTT group (Figure 2).The Journal of Thoracic and CTransplant hospitalization morbidity: Infection, dialysis,
and stroke (Figure 3). The EXTRA, PARA, and INTRA
groups all experienced increased incidence of infection.
The EXTRA group had increased risk of dialysis, stroke,
and primary graft failure at 30 days, whereas neither the
PARA nor the INTRA group differed from the non-BTT
group. Length of stay (Figure 4) was significantly longer
in all VAD groups compared with the non-BTT groups.
Long-term complications of transplantation: Renal fail-
ure, diabetes, transplant coronary artery disease, severe re-
jection (Figure 5). There were no differences in the incidence
rates of the long-term complications of transplantation be-
tween the non-BTT group and any of the VAD groups.
Implantable pulsatile devices versus continuous-flow
devices. When the INTRA group was further stratified
into continuous-flow and pulsatile groups and compared
with the non-BTT group by multivariate Cox regression
analysis, no differences in the following survival data
were found: risk-adjusted 90-day survival (pulsatile:
1.03, 0.70–1.50, P ¼ .888; continuous flow: 1.13,
0.58–2.20, P ¼ .722), 90-day to 1-year survival (pulsa-
tile: 0.78, 0.48–1.27, P ¼ .323; continuous flow: 1.15,
0.54–2.46, P ¼ .719), and 1-year to 5-year survival (pul-
satile: 0.82, 0.679–1.01, P ¼ .064; continuous-flow:T
XTABLE 1. Pretransplant recipient characteristics
Non-BTT INTRA P value* PARA P value* EXTRA P value* Total
No. 8346 1680 514 128 10,668
(%) 78.2 15.7 4.82 1.20 100.0
Recipient age (y) 52.2 50.5 <.001 46.3 <.001 49.1 .005 51.6
SD 12.3 11.4 14.2 13.7 12.3
Recipient BMI (kg/m2) 26.4 27.4 <.001 27.6 <.001 26.0 .4073 26.5
SD 4.8 5.1 5.1 4.5 4.9
Etiology: ischemic (n) 3708 822 <.001 220 .397 62 .245 4812
% 44.4 48.9 42.8 48.4 45.1
Etiology: DCM 3116 716 <.001 215 <.001 35 .029 4082
% 37.3 42.6 41.8 27.3 38.3
Wait time (d) 224.4 240.3 .13 152.1 <.001 79.0 <.001 221.6
SD 400.3 354.9 310.8 203.5 388.4
Status 1A (n) 2134 1071 <.001 395 <.001 109 <.001 3709
% 25.6 63.8 76.8 85.2 34.8
ICU at transplant (n) 2376 392 <.001 219 <.001 106 <.001 3093
% 28.5 23.3 42.6 82.8 29.0
Ventilator at transplant (n) 138 36 .172 43 <.001 59 <.001 276
% 1.7 2.1 8.4 46.1 2.6
Previous transplant (n) 250 9 <.001 11 .263 13 <.001 283
% 3.0 0.5 2.1 10.2 2.7
Inotropes at transplant (n) 4230 326 <.001 156 <.001 79 <.001 4791
% 50.7 19.4 30.4 61.7 44.9
Previous transplant within 90 days (n) 11 1 .434 5 <.001 13 <.001 30
% 0.1 0.1 1.0 10.2 0.3
Previous cardiac surgeryy (n) 1492 1015 .001 308 <.001 66 <.001 2881
% 17.9 60.4 59.9 51.6 27.0
Non-BTT,Nonbridge to transplant; INTRA, intracorporeal ventricular assist device; PARA, paracorporeal ventricular assist device; EXTRA, extracorporeal ventricular assist device.
SD, standard deviation; BMI, body mass index; DCM, dilated cardiomyopathy; ICU, intensive care unit. *P values determined using standard deviation at the comparison group.
yPrevious cardiac surgery excludes VAD implantation.ardiovascular Surgery c Volume 138, Number 6 1427
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XFIGURE 1. Kaplan–Meier unadjusted graft survival by group. Non-BTT, Nonbridge to transplant; INTRA, intracorporeal ventricular assist device; PARA,
paracorporeal ventricular assist device; EXTRA, extracorporeal ventricular assist device.0.79, 0.40–1.55, P ¼ .488). However, risk-adjusted graft
survival at more than 5 years was significantly better in
the pulsatile group (0.277, 0.122–0.627, P ¼ .002). The
continuous-flow group lacked sufficient follow-up to cal-
culate a hazard ratio beyond 5 years. In the pulsatile and
continuous-flow groups, only infection was increased
during the transplant hospitalization. There were no dif-
ferences in the incidence rates of long-term complications
in either pulsatile or continuous-flow groups when com-
pared with the non-BTT group.DISCUSSION
Findings here demonstrate that posttransplant survival
among recipients bridged to transplantation with LVADs
differs by device type. Among recipients bridged with ex-
tracorporeal devices (EXTRA group), survival was di-
minished in the short term (<90 days). However,
survival in recipients bridged with either paracorporeal
or intracorporeal implantable devices (PARA and INTRA
groups) was not statistically diminished from that of non-
bridged recipients (non-BTT group) at any posttransplantFIGURE 2. Hazard ratios and 95% confidence intervals for graft survival at follow-up intervals where compared with nonbridge.
1428 The Journal of Thoracic and Cardiovascular Surgery c December 2009
Russo et al Cardiothoracic TransplantationFIGURE 3. Odds ratios and 95% confidence intervals for in-hospital complications when compared with nonbridge. PGF, Primary graft failure at 30 days.T
Xtime interval (<90 days, 90 days–1 year, 1–5 years). Fur-
thermore, risk-adjusted survival at more than 5 years was
found to be significantly better in the INTRA group than
the non-BTT group.
Survival
In the EXTRA group, the diminished early survival is not
surprising. Extracorporeal devices are more frequently used
in acutely decompensated patients. Furthermore, these de-
vices are limited to shorter durations of support; therefore,
there is less opportunity to optimize candidates. As a result,
a large percentage of recipients supported with extracorpo-
real devices remain critically ill at the time of transplanta-
tion. This is reflected by higher percentages of EXTRA
recipients with status 1A listing, requiring inotropic support,
hospitalized in the intensive care unit, and intubated at the
time of transplant. In addition, more than 10% of EXTRA
recipients underwent a prior transplant within 90 days, com-
pared with less than 1.0% in the other 3 groups. Given the
retrospective nature of this study, a causal relationship be-
tween posttransplant survival and device type cannot be fur-
ther delineated. The diminished posttransplant survival in
the EXTRA group likely reflects, at least in part, differences
in the recipients and not inherent differences in the devices.
However, even if recipients with high-risk characteristics
such as retransplant within 90 days and/or intubation at the
time of transplantation were excluded from analysis, graft
survival at more than 90 days in multivariate regression re-
mained significantly worse among the EXTRA group.
INTRA and PARA groups achieved better posttransplant
outcomes than EXTRA recipients, although, compared with
the PARA group, both unadjusted and risk-adjusted survival
was better in the INTRA group.The Journal of Thoracic and CaDuring this study period, there was a trend toward better
risk-adjusted survival in the INTRA group than in the NB
group at later time points (90 days–1 year and 1–5 years). In-
terestingly, risk-adjusted survival at more than 5 years was
significantly better in the INTRA group than the NB group.
This is in contrast to the recent study6 of heart transplant re-
cipients between 1995 and 2004, which noted a significant
increase in late mortality among those bridged with intracor-
poreal devices. There is no clear explanation for better graft
survival at more than 5 years among the INTRA group com-
pared with the NB group found in this current study.
FIGURE 4. In-hospital mortality.rdiovascular Surgery c Volume 138, Number 6 1429
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that, when compared with the reference group, the INTRA
group had significantly better survival at 2 to 3 years and
a trend toward better survival at 4 to 5 years. This finding
may be related to the pretransplant characteristics in the IN-
TRA group, including lower mean age, higher percentage of
primary transplants, and lower percentage of congenital
etiology.
The conflicting findings between this current study and
the earlier study by Patlolla and associates6 regarding sur-
vival for more than 5 years may reflect the improvements
in outcomes during the more recent study period that are as-
sociated with operator learning curves, volume–outcome ef-
fect, and/or technological advances in intracorporeal device
therapy, including durability, greater ease of explant, and
more favorable adverse event profiles. Alternatively, they
may reflect the statistical limitations of analyzing this earlier
time period (Appendix E2). Other possible explanations for
the differing findings may result from differences in study
design, including the primary end point, inclusion/exclusion
criteria, and population of data fields. We chose to use graft
survival as the primary end point. In our opinion, graft sur-
vival has a number of advantages over patient survival. As
organs available for transplant remain critically scarce, fur-
ther expanding the benefit of transplantation is predicated
on improving the use of organs available for transplantation.
Analysis focusing on graft survival rather than patient sur-
vival better addresses this important issue. Moreover, if
recipients receive multiple transplants during the study
period, survival obtained after retransplantation is double
counted. That is, patient survival for recipients undergoing
transplantation twice during the study period is the sum of
survival as a result of the initial transplant plus the survival
after the second transplant; patient survival after the second
transplant will also be included in analysis as a second, dis-
FIGURE 5. Long-term complications of transplantation by group. *Trans-
plant coronary artery disease (TCAD) and severe rejection were reported as
incidence rates per 100 patient-years; renal failure was reported per 1000 pa-
tient-years. INTRA, Intracorporeal ventricular assist device; PARA, paracor-
poreal ventricular assist device; EXTRA, extracorporeal ventricular assist
device.1430 The Journal of Thoracic and Cardiovascular Sutinct observation, and thus be counted twice. Finally, using
patient survival in regression analysis significantly con-
founds the model by allowing for a bailout strategy of re-
transplant and introduces greater confounding by leaving
factors unaccounted for in the model, including the timing
of the retransplant, recipient clinical status at the time of
the repeat transplant, and characteristics of the donor in-
volved in the retransplant. A second difference between
this current study and the study by Patlolla and colleagues6
was that this current analysis included status 2 recipients and
retransplanted recipients. However, each of these variables
was accounted for in regression analysis; therefore, it is un-
likely that this difference should influence the findings.
Short- and Long-Term Morbidity
The VAD groups generally experienced greater perioper-
ative morbidity and longer lengths of stay. Not surprisingly,
the incidence of infection during the transplant hospitaliza-
tion was higher in all VAD groups. However, infection rates
were not lower in the INTRA group; this may reflect longer
duration of support. Furthermore, only the EXTRA group
had increased risks of dialysis, stroke, and primary graft fail-
ure at 30 days compared with the non-BTT group. Finally,
consistent with previous studies,11-13 the long-term compli-
cations of transplantation, including the incidence of chronic
dialysis, transplant coronary artery disease, and severe rejec-
tion, did not differ across groups.
Pulsatile Versus Continuous-Flow Devices
Secondary analysis further stratified the INTRA group
into 2 subgroups, pulsatile and continuous flow.When either
of these groups was compared with the NB group, there was
no statistical difference in graft survival, in-hospital morbid-
ity, or long-term complications of transplantation except at
more than 5 years, where graft survival, as in the INTRA
group, was significantly better in recipients bridged with
pulsatile devices.
Implications
First, although heart transplant recipients bridged to trans-
plantationwithVADs are typically considered to be at higher
risk in the posttransplant period, findings from this analysis
demonstrate that outcomes differ by device type. This may
be due to differences in baseline characteristics and operative
procedures. Recipients bridgedwith implantable devices still
achieve the same unadjusted survival as nonbridged recipi-
ents. In contrast, candidates supported by extracorporeal de-
vices remain at high risk in the early posttransplant period.
However, the diminished posttransplant survival in the EX-
TRA group may, at least in part, reflect differences in the re-
cipients and not inherent differences in the devices.
These findings presented here—in conjunction with
a number of recent studies demonstrating that more than
80% of well-selected patients implanted with intracorporealrgery c December 2009
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planted14,15—provide additional evidence that more aggres-
sive use of implantable devices may benefit candidates
whose condition is refractory to medical management. Be-
cause outcomes are best when implantable device support
is implemented before patients acutely decompensate,14,15
these findings further suggest that more aggressive use of
implantable support may benefit candidates who are likely
to face long waiting times, such as candidates with higher
body mass index or blood type O. Conversely, this analysis
found that during the study period recipients bridged with
extracorporeal devices possessed high-risk characteristics
and achieved inferior outcomes in the early posttransplant
period. Therefore, candidates supported by an extracorpo-
real device may benefit from further optimization before
transplantation, and extracorporeal devices may best be
used as a bridge to an implantable device. However, given
the retrospective nature of this study, additional studies ex-
amining outcomes among heart transplant candidates during
both waiting and posttransplant periods are needed. Further-
more, an additional analysis should focus on assessing the
survival of heart transplant candidates on the waiting list
in the absence of mechanical support.
Limitations
Patient registries often suffer from data entry variability.
However, fields contained within this database were gener-
ally well populated with a 95% to 99% data entry rate for
the majority of variables. Although the UNOS reporting sys-
tem provided variable definitions in data guidelines, definitions
may still differ by center. Second, the limited time points for
collection of data in the UNOS registry (at listing, at transplan-
tation, and at follow-up) preclude the analysis of clinical status
at the time of device implantation or over the course of me-
chanical support. As such, we could not analyze the length
of time supported by a particular device, which might have
been a particularly strong predictor of end-organ dysfunction
and poor outcome. Nevertheless, future studies are needed to
better elucidate the important and complex relationship be-
tween time on device support and posttransplant outcomes.
Device information for recipients was missing in a small
number of cases and was ambiguous in others. Devices desig-
nated as only as ‘‘Abiomed’’ were classified as ‘‘Abiomed
BVS5000,’’ and devices designated as only as ‘‘Thoratec’’
were classified as ‘‘Thoratec PVAD.’’ Regardless, this is un-
likely to have a significant impact on the findings. During
the study period, the experience with the Abiomed AB 5000
device was limited to approximately 25 patients,16 and post-
transplant outcomes in recipients bridged with the Thoratec de-
vices—PVAD, HMI, and HMII—did not differ significantly.
Although our regression model demonstrated moderate
discrimination, significant variability remains unexplained.
We speculate that some of the variability stems from func-
tional status, health variables, and technical aspects of theThe Journal of Thoracic and Cprocedure that were not captured by the UNOS data set.
As a result, differences among the EXTRA, PARA, and
INTRA groups may, at least in part, reflect differences in
the recipients and not inherent differences related to the de-
vices types.
CONCLUSIONS
Posttransplantation graft survival in recipients bridged to
transplantation with LVADs differs by VAD type. During
the study period, the use of implantable LVADs as bridges
to transplantation, including both intracorporeal and para-
corporeal devices, was not associated with diminished
risk-adjusted posttransplant graft survival compared with
nonbridged recipients. However, risk-adjusted posttrans-
plant graft survival at less than 90 days was diminished in
recipients bridged with extracorporeal devices.
These findings support the aggressive use of implantable
devices in candidates who are refractory to medical manage-
ment, especially those who are expected to encounter long
waiting times. Conversely, outcomes in the EXTRA group
suggest that the candidates supported by an extracorporeal
device may need further optimization before transplantation;
therefore, extracorporeal devices may best be used as
a bridge to an implantable device. Nevertheless, given the
retrospective nature of this study, additional studies examin-
ing outcomes among heart transplant candidates during both
waiting and posttransplant periods are needed.
We thank UNOS for supplying this data and Katarina Anderson,
PhD, for her assistance with our analysis.
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XAPPENDIX E1. Multivariate Cox proportional hazards regression
analysis
VAD type
by posttransplant
interval Hazard ratio
95% Confidence interval
95%
CI LL
95%
CI UL P value
0–90 days
Intracorporeal 1.040 0.715 1.505 .834
Paracorporeal 1.064 0.642 1.764 .809
Extracorporeal 3.540 2.275 5.507 <.001
90 days–1 year
Intracorporeal 0.760 0.541 1.069 .115
Paracorporeal 1.164 0.636 2.131 .621
Extracorporeal 1.826 0.834 3.997 .132
1–5 years
Intracorporeal 0.818 0.665 1.007 .058
Paracorporeal 0.723 0.457 1.145 .166
Extracorporeal 0.890 0.381 2.081 .788
>5 years
Intracorporeal 0.389 0.205 0.738 .004
Paracorporeal 0.728 0.298 1.780 .487
Extracorporeal 0.625 0.070 5.558 .674
Other variables
Etiology: congenital 1.592 1.259 2.012 <.001
Recipient GFR 0.988 0.985 0.991 <.001
Recipient total bilirubin 1.039 1.027 1.051 <.001
Etiology: amyloid 2.615 1.541 4.437 <.001
Donor age 1.010 1.006 1.013 <.001
Hep C (þ) donor 2.286 1.532 3.410 <.001
Recipient GFR 3 time (y) 0.865 0.798 0.939 <.001
OHT center volume 0.996 0.994 0.999 .001
Ischemic time 3 time (y) 0.958 0.935 0.982 .001
Intubated at transplant 3
time (y)
0.753 0.630 0.900 .002
Etiology: congenital 3
time (y)
0.787 0.672 0.921 .003
Donor/recipient weight
ratio<0.7
1.346 1.092 1.660 .005
Intubated at transplant 1.452 1.119 1.885 .005
Recipient diabetes
mellitus
1.164 1.044 1.298 .006
Ischemic time 1.065 1.018 1.113 .006
CMV (þ) recipient 1.211 1.052 1.394 .008
Recipient age 3 time (y) 0.997 0.995 0.999 .009
Recipient CVA3 time (y) 0.871 0.781 0.970 .012
Female donor/female
recipient
1.143 1.022 1.278 .019
Etiology: HCM3 time (y) 0.729 0.557 0.953 .021
Donor DM>6 years 3
time (y)
0.612 0.389 0.963 .034
Hospitalized at transplant 1.127 1.005 1.263 .041
Reoperation 1.107 0.992 1.234 .069
Male donor/female
recipient
1.106 0.972 1.259 .127
CMV () recipient/(þ)
donor
1.134 0.965 1.334 .128
Status 1A 1.097 0.969 1.242 .145
APPENDIX E1. Continued
VAD type
by posttransplant
interval Hazard ratio
95% Confidence interval
95%
CI LL
95%
CI UL P value
DM complicated by PVD
or CKD
1.192 0.937 1.516 .153
ICU at transplant 0.902 0.780 1.042 .161
Recipient age 0.997 0.992 1.002 .190
Recipient underweight 1.173 0.922 1.494 .195
Donor history of cancer 0.801 0.540 1.186 .268
Etiology: valvular 0.854 0.640 1.139 .282
Transplant year 1.017 0.986 1.050 .285
BMI obesity
class II/III
1.110 0.890 1.385 .354
Etiology: ischemic 1.051 0.938 1.176 .391
Etiology: HCM 0.849 0.580 1.242 .399
Status 1B 1.080 0.903 1.292 .400
BiVAD at transplant 1.172 0.805 1.705 .407
Female donor/male
recipient
1.082 0.898 1.304 .409
Hep C (þ) recipient 1.120 0.840 1.493 .440
Recipient CVA 1.076 0.893 1.295 .442
Donor cause
of death: cancer
1.221 0.726 2.054 .452
Etiology: other 0.901 0.683 1.189 .462
Corticosteroids at
transplant
1.061 0.903 1.246 .471
Donor cause
of death: hypertension
1.059 0.899 1.247 .494
Insulin-dependent donor 1.182 0.625 2.236 .607
Recipient COPD 1.057 0.826 1.352 .660
Etiology: sarcoid 0.819 0.305 2.196 .691
No. of previous
heart transplants
1.073 0.730 1.577 .721
Donor DM>6 years 1.118 0.568 2.201 .746
Donor cause
of death: CVA
1.029 0.859 1.233 .754
Corticosteroids at
transplant 3 time (y)
1.008 0.932 1.090 .837
Corticosteroids at
transplant 3 time (y)
1.019 0.609 1.706 .943
Previous OHT within 90
days
1.003 0.436 2.309 .994
VAD, Ventricular assist device; CI, confidence interval; LL, lower limit; UL, upper
limit; GFR, glomerular filtration rate; Hep C, hepatitis C; OHT, orthotopic heart trans-
plant; CMV, cytomegalovirus; CVA, cerebrovascular accident; HCM, hypertrophic
cardiomyopathy; DM, diabetes mellitus; PVD, peripheral vascular disease; CKD,
chronic kidney disease; ICU, intensive care unit; BiVAD, biventricular assist device;
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On the basis of our analysis of the UNOS database, it ap-
pears that the study reported by Patlolla and associates6 is
plagued by missing data. During the 1995 to 2004 time pe-
riod, UNOS reported that 13,891 status 1/1A/1B recipients
underwent transplantation. On the basis of the study’s exclu-
sion criteria—retransplantation (n ¼ 233), VAD and intra-
aortic balloon pump concurrently (n ¼ 185), multiorgan
transplant (n ¼ 238), 13,258 met inclusion criteria. How-
ever, Patlolla and associates6 included only 11,336 status 1
recipients in their analysis. Furthermore, we identified
2788 status 1 BTT recipients who met inclusion criteria;
however the study in the Journal of the American College
of Cardiology included only 1881 BTT recipients in the
analysis.
Determining VAD type in the UNOS registry is compli-
cated. VAD type is not coded by a single field. Rather, it may
be indicated in as many as 8 separate fields: vad_brand1_trr,
vad_brand2_trr, vad_tah_trr, vad_device_ty_trr, vad_bran-
d1_ostxt_trr, vad_brand2_ostxt_trr, vad_tah_ostxt_trr, and
oth_life_sup_ostxt_trr. The last 4 fields are free text and
require that analysts search observations by hand to ensure
accurate categorization. Furthermore, in 1999, UNOS
expanded the data entry options, thus improving the ability
of centers to more clearly specify VAD type. Before this,
a significant portion of bridged recipients were merely coded
as ‘‘LVAD,’’ ‘‘VAD,’’ or ‘‘VAD/unspecified.’’ Therefore,
VAD type (intracorporeal vs extracorporeal) cannot be
determined. As summarized below ‘‘VAD/unspecified’’ de-
scribed more than 70% of the recipients bridged to trans-
plant before 1999 (Appendix E2 Table).
On the basis of theMethods section contained in the article,
it was difficult to understand how the authors dealt with recip-
ients with missing data. In addition, it is unclear from the
manuscript how they accounted for the DeBakey, Jarvik,
HeartMate 2, Thoratec and IVAD devices, as well as
total artificial hearts and extracorporeal membrane oxygena-
tion—all of which were used to successfully bridge recipients
to transplantation during their study period. Moreover, we
disagree with the classification of VAD type in the study by
Patlolla and associates.6 In their analysis, the intracorporeal
VAD group included patients on a HeartMate (Thoratec Cor-
poration, Pleasanton, Calif) or Novacor (World Heart Inc,
Oakland, Calif) intracorporeal VAD. The extracorporeal1432.e2 The Journal of Thoracic and Cardiovascular SVAD group included patients with a Thoratec (Thoractec
Corporation) or Abiomed (Abiomed Inc, Danvers, Mass) ex-
tracorporeal VAD. However, we consider the Thoratec de-
vice to be a paracorporeal, not extracorporeal device.
Based on of communication with the Journal of the Amer-
ican College of Cardiology authors, they included only
specified VAD types—HeartMate and Novacor in the intra-
corporeal group and Thoratec and Abiomed devices in the
extracorporeal group. If the type was another device type
or ‘‘unspecified,’’ they assumed that the device was not
one of these devices, and they excluded the recipient from
analysis. This strategy has significant limitations, unless it
is assumed that the missing data were random. However,
given the high proportion of missing data, this is a poor as-
sumption.
The Journal of the American College of Cardiology arti-
cle’s most significant finding was that late (>5 years), but not
early, survival differed in the implantable device group com-
pared with the non-BTT group. This finding is significant
because previous studies comparing posttransplant out-
comes in BTT and non-BTT recipients, like most studies
comparing ‘‘high-risk’’ surgical populations and standard
populations, generally found that the BTT population falls
into 1 of 3 categories: (1) no survival difference, (2) early
(first 90 days to 1 year) survival difference with this differ-
ence persisting over the long term, and (3) early survival dif-
ference with no difference over the long term. To have
a difference in late but not early survival is inconsistent
with previously published studies of this population. Fur-
thermore, with previous studies concluding that the long-
term complications of transplantation, including rejection,
infection, and transplant coronary artery disease, do not dif-
fer in these groups, there is no obvious clinical explanation
for this finding.
Any analysis of the time period including 1995 through
1999 is significantly confounded by missing data. For the
Journal of the American College of Cardiology article,
this issue of confounding is most relevant in this later fol-
low-up period. In this study, follow-up data were available
only through 2006; therefore, recipients with greater than
5 years of follow-up underwent transplantation in the period
of 1995 to 2000. During this era, by our analysis, signifi-
cantly more than 50% of the study group was dropped
from analysis. Therefore, it is difficult to draw any conclu-
sions regarding this time period.urgery c December 2009
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Year EXTRA INTRA PARA
VAD/
unspecified Total
1995 2 24 0 132 158
1.27 15.2 0 83.5
1996 1 29 3 173 206
0.49 14.1 1.46 84.0
1997 0 53 1 188 242
0 21.9 0.41 77.7
1998 7 63 1 166 237
2.95 26.6 0.42 70.0
1999 8 123 7 122 260
3.08 47.3 2.7 46.9
2000 23 256 20 3 302
7.62 84.7 6.6 0.99
2001 29 288 86 0 403
7.2 71.5 21.3 0
2002 14 262 64 3 343
4.08 76.4 18.7 0.87
2003 10 239 89 4 342
2.92 69.9 26.0 1.17
2004 6 247 37 5 295
2.03 83.7 12.5 1.69
Total 100 1584 308 796 2788
3.59 56.8 11.1 28.6
EXTRA, Extracorporeal ventricular assist device. INTRA, intracorporeal ventricular
assist device; PARA, paracorporeal ventricular assist device; VAD, ventricular assist
device.
EXTRA devices included Abiomed BVS5000, Tandem, Bio-Medicus, and Levitro-
nix/Centrimag. PARA devices included Abiomed AB5000, Thoratec PVAD, and
Toyobo. INTRA devices included pulsatile devices (Novacor, HeartMate I, Thoratec
IVAD, and LionHeart) and continuous-flow devices (HeartMate II, MicroMed/De
Bakey, Jarvik, and Ventracor/VentrAssist). Patients who had previously undergone
transplantation or were also on an intra-aortic balloon pump were excluded.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 6 1432.e3
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